This is a phase III, multicenter, randomized, single blind study designed to evaluate the efficacy and tolerability of a single dose of parecoxib compared with diclofenac in the treatment of acute pain due to renal colic...
Date First Received: August 29, 2005
Last Updated: May 2, 2008
Verified by: Pfizer, May 2008
Clinical Trial Phase: Phase 3 | Start Date: April 2002
Overall Status: Terminated
Estimated Enrollment: 50
Brief Summary
Official Title: “A Multicenter Single-Blind, Single Dose Efficacy and Safety Pilot Study Comparing Intramuscular Parecoxib and Diclofenac in Renal Colic”
Condition Keyword(s):
Intervention(s):
This is a phase III, multicenter, randomized, single blind study designed to evaluate the efficacy and tolerability of a single dose of parecoxib compared with diclofenac in the treatment of acute pain due to renal colic.
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Detailed Clinical Trial Description
This study was prematurely discontinued May 3, 2004 due to slow recruitment. The decision to terminate the trial was not based on any safety concerns.
Intervention(s) in this Clinical Trial
- Drug: Parecoxib
- Drug: Diclofenac
Outcome Measures for this Clinical Trial
Primary Measures
- Evaluation of efficacy through: time to onset of pain relief and time to remedication.
Secondary Measures
- Evaluation of efficacy through: Pain Intensity (VAS), Pain Relief (PR) and several measurements of analgesia that will be derived from VAS and PR Physician's Global Evaluation at 12 hours Patient's Global Evaluation at 12 hours
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- diagnosis of renal colic;
- baseline pain > 50 mm on VAS;
Exclusion Criteria:
- evidence of neoplasm or any other severe disease of any organ, including any psychiatric illness;
- active GI disease (e.g. Crohn's disease or ulcerative colitis) or any evidence of concomitant disease which may lead to early termination of the study
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 65 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Pfizer
Overall Clinical Trial Officials and Contacts
Pfizer CT.gov Call Center Study Director Pfizer
Additional Information
Information obtained from ClinicalTrials.gov on August 29, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00139646
Study ID Number: 124-IFL-0505-005
ClinicalTrials.gov Identifier: NCT00139646
Health Authority: Italy: Ministry of Health
To obtain contact information for a study center near you, click here.
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.